Liège-based Contipharma has registered a patent for a rapid saliva antigen test in the fight against malaria, it announced Monday via a press release.
“Current diagnostic tests for malaria are often unsatisfactory; they are too complex or expensive, and require sanitary equipment that is not always accessible or disfavored by the community,” confirms Hope Sunovo, Scientific Director of Contipharma.
Malaria (or malaria) is a fatal disease that can be transmitted to humans through the bites of certain types of mosquitoes. It occurs mainly in tropical countries. It is a preventable and treatable disease.
The World Health Organization estimates that there will be 249 million cases of malaria in 2022 and 608,000 deaths from the disease in 85 countries.
The Liège-based company was founded in 2015 and is a major logistics platform for the distribution of health products in Europe.
Access to all features is reserved for healthcare professionals.
If you are a healthcare professional, you must log in or register for free on our site to access all of our content.
If you are a journalist or if you would like to let us know, write to us at [email protected].
